Prime Medicine said its FY 2025 net loss attributable to common stockholders was USD 201.1 million, with a net loss per share of USD 1.35. Total revenue for FY 2025 was USD 4.6 million, including USD 4.6 million in collaboration revenue from a related party. R&D expenses totaled USD 160.6 million in FY 2025, while G&A expenses were USD 52.3 million. As of Dec. 31, 2025, cash, cash equivalents, investments and restricted cash were USD 191.4 million, which the company said is expected to fund operations into 2027. On the pipeline, Prime Medicine said it remains on track to submit an IND and/or CTA for its Wilson Disease program in 1H 2026 and for its Alpha-1 Antitrypsin Deficiency program in mid-2026, with initial clinical data for both expected in 2027. For PM359 in chronic granulomatous disease, the company said it is continuing engagement with the FDA and intends to submit a BLA following final alignment, citing its view that clinical data generated to date may be sufficient to support an accelerated approval. Prime Medicine also said it expects preclinical proof-of-concept data in 2026 for its in vivo cystic fibrosis program and highlighted ongoing Prime Edited CAR-T work in partnership with Bristol Myers Squibb.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664426) on March 03, 2026, and is solely responsible for the information contained therein.